Independent Director 2025 Annual Performance Report
To all shareholders and shareholder representatives:
As an independent director of Maccura Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") for the sixth board of directors, in 2025, I have strictly followed the requirements of relevant laws and regulations such as the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Administrative Measures for Independent Directors of Listed Companies" (hereinafter referred to as the "Administrative Measures"), the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 2 - Norms for Operation of Companies Listed on the ChiNext Market" (hereinafter referred to as the "ChiNext Market Operation Guidelines"), and the rights and obligations granted by the "Company Articles of Association" and the "Work System for Independent Directors." I have honestly, diligently, and conscientiously performed my duties, kept abreast of the Company's production, operation, and development, actively attended relevant meetings, diligently reviewed all proposals, leveraged my professional expertise, provided constructive suggestions for the Company's operational development, and effectively protected the overall interests and legal rights and interests of all shareholders.
Herein is a report on my fulfillment of independent director duties in 2025:
I. Personal Information, Qualifications, and Independence Statement
I, Mr. Liang Kaicheng, born in 1956, am a Chinese national with no permanent overseas residency and hold a college degree. I have consistently focused on the field of in vitro diagnostics, with extensive experience in the research and development, operation, and application of in vitro diagnostic products, accumulating decades of industry experience and a profound understanding of the in vitro diagnostics field. I have served as an independent director of the Company since January 17, 2022.
I possess the requisite qualifications for an independent director of a listed company and hold an independent director qualification certificate. I do not serve as an independent director for more than three listed companies concurrently and have no disqualifications from serving as an independent director. During my tenure as an independent director of the Company, neither I nor my immediate family members hold any positions in the Company or its subsidiaries other than independent director, nor do we hold any positions with the Company's principal shareholders. There are no relationships between me, the Company, and its principal shareholders that would hinder my independent and objective judgment. I have not provided financial, legal, or consulting services to the Company or its subsidiaries. Apart from the fixed independent director allowance, I have not received any additional undisclosed benefits from the Company, its principal shareholders, or related parties, and there are no circumstances that affect my independence as an independent director. This complies with the requirements of the "Administrative Measures," "ChiNext Market Operation Guidelines," and other relevant laws, regulations, and normative documents, as well as the "Company Articles of Association" and the "Work System for Independent Directors" regarding the independence of independent directors.
II. Performance in 2025
(I) Attendance at Board and Shareholder Meetings
I have diligently reviewed all proposals submitted to the Board of Directors, maintained close communication with the Company's management, continuously understood the Company's operating conditions, and offered reasonable suggestions, exercising my voting rights with prudence and diligence. I believe that the convening and holding of the Company's 2025 Board of Directors and shareholder meetings complied with legal procedures, and that major operational and other significant decisions underwent the relevant procedures and were legal and valid. Therefore, I voted in favor of all proposals at the Company's 2025 Board of Directors meetings, with no objections or abstentions. My attendance at meetings in 2025 is as follows: